Advanced search
Publication Cover
Future Oncology Volume 8, 2012 - Issue 12
Submit an article Journal homepage
265
Views
0
CrossRef citations to date
0
Altmetric
Review

Recent Progress in Managing Graft-Versus-Host Disease and Viral Infections Following Allogeneic Stem Cell Transplantation

Rob S Sellar1 UCL Cancer Institute, Department of Haematology, London, WC1E 6BT, UKView further author information
&
Karl S Peggs1 UCL Cancer Institute, Department of Haematology, London, WC1E 6BT, UK;1 UCL Cancer Institute, Department of Haematology, London, WC1E 6BT, UK. [email protected]Correspondence[email protected]
View further author information
Pages 1549-1565 | Published online: 12 Dec 2012

References

  • Fernandez HF , SunZ, YaoXet al. Anthracycline dose intensification in acute myeloid leukemia. N. Engl. J. Med. 361(13), 1249–1259 (2009).
  • Topp MS , KuferP, GokbugetNet al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29(18), 2493–2498 (2011).
  • Pettitt AR , JacksonR, CarruthersSet al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J. Clin. Oncol. 30(14), 1647–1655 (2012).
  • Chen R , PalmerJM, ThomasSHet al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 119(26), 6379–6381 (2012).
  • Lambert JR , BomanjiJB, PeggsKSet al. Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. Blood 115(14), 2763–2768 (2010).
  • Apperley JF , MauroFR, GoldmanJMet al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br. J. Haematol. 69(2), 239–245 (1988).
  • Pasquini MC , WangZ, HorowitzMM, GaleRP. 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders.Clin. Transpl.2010, 87–105 (2010).
  • Poire X , van BesienK. Alemtuzumab in allogeneic hematopoetic stem cell transplantation.Expert Opin. Biol. Ther.11(8), 1099–1111 (2011).
  • Kottaridis PD , MilliganDW, ChopraRet?al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96(7), 2419–2425 (2000).
  • Chakraverty R , PeggsK, ChopraRet al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99(3), 1071–1078 (2002).
  • Mead AJ , ThomsonKJ, MorrisECet al. HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. Blood 115(25), 5147–5153 (2010).
  • Kanda Y , OshimaK, Asano-MoriYet?al. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation 79(10), 1351–1357 (2005).
  • Barge RM , StarrenburgCW, FalkenburgJH, FibbeWE, MarijtEW, WillemzeR. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath ‘in the bag’ as T-cell depletion: the Leiden experience.Bone Marrow Transplant.37(12), 1129–1134 (2006).
  • Peggs KS , HunterA, ChopraRet al. Clinical evidence of a graft-versus-Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 365(9475), 1934–1941 (2005).
  • Veys P , WynnRF, AhnKWet al. Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia. Blood 119(25), 6155–6161 (2012).
  • Landgren O , GilbertES, RizzoJDet al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 113(20), 4992–5001 (2009).
  • Finke J , BethgeWA, SchmoorCet al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre Phase 3 trial. Lancet Oncol. 10(9), 855–864 (2009).
  • Socie G , SchmoorC, BethgeWAet al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 117(23), 6375–6382 (2011).
  • Kumar A , MhaskarAR, ReljicTet al. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia 26(4), 582–588 (2012).
  • Schultz KR , PaquetJ, BaderS, HayGlassKT. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease.Bone Marrow Transplant16(2), 289–295 (1995).
  • Knoechel B , LohrJ, KahnE, AbbasAK. The link between lymphocyte deficiency and autoimmunity: roles of endogenous T and B lymphocytes in tolerance.J. Immunol.175(1), 21–26 (2005).
  • Shimabukuro-Vornhagen A , HallekMJ, StorbRF, von Bergwelt-BaildonMS. The role of B cells in the pathogenesis of graft-versus-host disease.Blood114(24), 4919–4927 (2009).
  • Ratanatharathorn V , LoganB, WangDet al. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br. J. Haematol. 145(6), 816–824 (2009).
  • Crocchiolo R , CastagnaL, El-CheikhJet al. Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients. Exp. Hematol. 39(9), 892–896 (2011).
  • van Dorp S , PietersmaF, WolflMet al. Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD. Biol. Blood Marrow Transplant. 15(6), 671–678 (2009).
  • Khouri IF , SalibaRM, GiraltSAet al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98(13), 3595–3599 (2001).
  • Khouri IF , McLaughlinP, SalibaRMet al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111(12), 5530–5536 (2008).
  • Khouri IF , SalibaRM, AdmirandJet al. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br. J. Haematol. 137(4), 355–363 (2007).
  • Glass B , HasenkampJ, GorlitzAet al. Rituximab for graft-versus-host-disease-prophylaxis after allogeneic stem cell transplantation given as treatment of high risk relapse of aggressive lymphoma: results of a randomized Phase II study. ASH Annu. Meeting Abstracts 112(11), 1974 (2008).
  • Dominietto A , TedoneE, SoraccoMet?al. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT. Bone Marrow Transplant. 47(1), 101–106 (2012).
  • McIver Z , StephensN, GrimA, BarrettAJ. Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias.Biol. Blood Marrow Transplant.16(11), 1549–1556 (2010).
  • Schnitzler M , HasskarlJ, EggerM, BertzH, FinkeJ. Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab.Biol. Blood Marrow Transplant.15(8), 910–918 (2009).
  • Gomez-Almaguer D , Ruiz-ArguellesGJ, del Carmen Tarin-ArzagaLet al. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol. Blood Marrow Transplant. 14(1), 10–15 (2008).
  • Martinez C , SolanoC, FerraC, SampolA, ValcarcelD, Perez-SimonJA. Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a Phase II study.Biol. Blood Marrow Transplant.15(5), 639–642 (2009).
  • Schub N , GuntherA, SchrauderAet al. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Bone Marrow Transplant. 46(1), 143–147 (2011).
  • Adkins D , RatanatharathornV, YangH, WhiteB. Safety profile and clinical outcomes in a Phase I, placebo-controlled study of siplizumab in acute graft-versus-host disease.Transplantation88(2), 198–202 (2009).
  • Brochstein JA , GruppS, YangH, PillemerSR, GebaGP. Phase-1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft-versus-host disease.Pediatr. Transplant.14(2), 233–241 (2010).
  • Carpenter PA , AppelbaumFR, CoreyLet al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 99(8), 2712–2719 (2002).
  • Carpenter PA , LowderJ, JohnstonLet al. A Phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol. Blood Marrow Transplant. 11(6), 465–471 (2005).
  • Brown GR , LindbergG, MeddingsJ, SilvaM, BeutlerB, ThieleD. Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease.Gastroenterology116(3), 593–601 (1999).
  • Stuber E , BuschenfeldA, von FreierA, ArendtT, FolschUR. Intestinal crypt cell apoptosis in murine acute graft versus host disease is mediated by tumour necrosis factor α and not by the FasL-Fas interaction: effect of pentoxifylline on the development of mucosal atrophy.Gut45(2), 229–235 (1999).
  • Choi SW , KitkoCL, BraunTet al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 112(4), 1539–1542 (2008).
  • Willems E , Humblet-BaronS, DengisO, SeidelL, BeguinY, BaronF. Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Bone Marrow Transplant.45(9), 1442–1448 (2010).
  • Levine JE , PaczesnyS, MineishiSet al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 111(4), 2470–2475 (2008).
  • Alousi AM , WeisdorfDJ, LoganBRet al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized Phase 2 trial from the blood and marrow transplant clinical trials network. Blood 114(3), 511–517 (2009).
  • Busca A , LocatelliF, MarmontF, CerettoC, FaldaM. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.Am. J. Hematol.82(1), 45–52 (2007).
  • Patriarca F , SperottoA, DamianiDet al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 89(11), 1352–1359 (2004).
  • Couriel D , SalibaR, HicksKet al. Tumor necrosis factor-α blockade for the treatment of acute GVHD. Blood 104(3), 649–654 (2004).
  • Hamadani M , HofmeisterCC, JansakBet al. Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. Biol. Blood Marrow Transplant. 14(7), 783–789 (2008).
  • Couriel DR , SalibaR, de LimaMet al. A Phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol. Blood Marrow Transplant. 15(12), 1555–1562 (2009).
  • Jacobsohn DA , HallickJ, AndersV, McMillanS, MorrisL, VogelsangGB. Infliximab for steroid-refractory acute GVHD: a case series.Am. J. Hematol.74(2), 119–124 (2003).
  • Sleight BS , ChanKW, BraunTM, SerranoA, GilmanAL. Infliximab for GVHD therapy in children.Bone Marrow Transplant.40(5), 473–480 (2007).
  • Pidala J , KimJ, FieldTet al. Infliximab for managing steroid-refractory acute graft-versus-host disease. Biol. Blood Marrow Transplant. 15(9), 1116–1121 (2009).
  • Anasetti C , HansenJA, WaldmannTAet al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 84(4), 1320–1327 (1994).
  • Przepiorka D , KernanNA, IppolitiCet al. Daclizumab, a humanized anti-interleukin-2 receptor α chain antibody, for treatment of acute graft-versus-host disease. Blood 95(1), 83–89 (2000).
  • Srinivasan R , ChakrabartiS, WalshTet al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br. J. Haematol. 124(6), 777–786 (2004).
  • Rao K , RaoA, KarlssonH, JaganiM, VeysP, AmroliaPJ. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease.J. Pediatr. Hematol. Oncol.31(6), 456–461 (2009).
  • Rager A , FreyN, GoldsteinSCet al. Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD. Bone Marrow Transplant. 46(3), 430–435 (2011).
  • Bordigoni P , DimicoliS, ClementLet al. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br. J. Haematol. 135(3), 382–385 (2006).
  • Wolff D , RoesslerV, SteinerBet al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant. 35(10), 1003–1010 (2005).
  • Lee SJ , ZahriehD, AguraEet al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 104(5), 1559–1564 (2004).
  • Schmidt-Hieber M , FietzT, KnaufWet al. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br. J. Haematol. 130(4), 568–574 (2005).
  • Massenkeil G , RackwitzS, GenvresseI, RosenO, DorkenB, ArnoldR. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.Bone Marrow Transplant.30(12), 899–903 (2002).
  • Funke VA , de MedeirosCR, SetubalDCet al. Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. Bone Marrow Transplant. 37(10), 961–965 (2006).
  • Pinana JL , ValcarcelD, MartinoRet al. Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease. Biol. Blood Marrow Transplant. 12(11), 1135–1141 (2006).
  • Bay JO , DhedinN, GoernerMet al. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies. Transplantation 80(6), 782–788 (2005).
  • Bettelli E , CarrierY, GaoWet al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T-cells. Nature 441(7090), 235–238 (2006).
  • Veldhoen M , HockingRJ, AtkinsCJ, LocksleyRM, StockingerB. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T-cells.Immunity24(2), 179–189 (2006).
  • Symington FW , SymingtonBE, LiuPY, ViguetH, SanthanamU, SehgalPB. The relationship of serum IL-6 levels to acute graft-versus-host disease and hepatorenal disease after human bone marrow transplantation.Transplantation54(3), 457–462 (1992).
  • Ambruzova Z , MrazekF, RaidaLet al. Association of IL6 and CCL2 gene polymorphisms with the outcome of allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 44(4), 227–235 (2009).
  • Cavet J , DickinsonAM, NordenJ, TaylorPR, JacksonGH, MiddletonPG. Interferon-γ and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation.Blood98(5), 1594–1600 (2001).
  • Tawara I , KoyamaM, LiuCet al. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin. Cancer Res. 17(1), 77–88 (2011).
  • Chen X , DasR, KomorowskiRet al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood 114(4), 891–900 (2009).
  • Drobyski WR , PasquiniM, KovatovicKet al. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol. Blood Marrow Transplant. 17(12), 1862–1868 (2011).
  • Betts BC , St AngeloET, KennedyM, YoungJW. Anti-IL6-receptor-α (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses.Blood118(19), 5340–5343 (2011).
  • Sidiropoulos PI , BoumpasDT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients.Lupus13(5), 391–397 (2004).
  • Socie G , BlazarBR. Acute graft-versus-host disease: from the bench to the bedside.Blood114(20), 4327–4336 (2009).
  • Polchert D , SobinskyJ, DouglasGet al. IFN-γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur. J. Immunol. 38(6), 1745–1755 (2008).
  • Sudres M , NorolF, TrenadoAet al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J. Immunol. 176(12), 7761–7767 (2006).
  • Le Blanc K , RasmussonI, SundbergBet al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363(9419), 1439–1441 (2004).
  • Ringden O , UzunelM, RasmussonIet al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81(10), 1390–1397 (2006).
  • Le Blanc K , FrassoniF, BallLet al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a Phase II study. Lancet 371(9624), 1579–1586 (2008).
  • Kebriaei P , IsolaL, BahceciEet al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol. Blood Marrow Transplant. 15(7), 804–811 (2009).
  • Allison M . Genzyme backs osiris, despite prochymal flop.Nat. Biotechnol.27(11), 966–967 (2009).
  • Lucchini G , DanderE, PavanFet al. Mesenchymal stromal cells do not increase the risk of viral reactivation nor the severity of viral events in recipients of allogeneic stem cell transplantation. Stem Cells Int. 2012, 690236 (2012).
  • Forslow U , BlennowO, LeblancKet al. Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation. Eur. J. Haematol. 89(3), 220–227 (2012).
  • Ning H , YangF, JiangMet al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 22(3), 593–599 (2008).
  • Sun K , WelniakLA, Panoskaltsis-MortariAet al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc. Natl Acad. Sci. USA 101(21), 8120–8125 (2004).
  • Koreth J , StevensonKE, KimHTet al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 114(18), 3956–3959 (2009).
  • Ratanatharathorn V , AyashL, ReynoldsCet al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol. Blood Marrow Transplant. 9(8), 505–511 (2003).
  • Kharfan-Dabaja MA , MhaskarAR, DjulbegovicB, CutlerC, MohtyM, KumarA. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis.Biol. Blood Marrow Transplant.15(9), 1005–1013 (2009).
  • Zaja F , BacigalupoA, PatriarcaFet al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant. 40(3), 273–277 (2007).
  • Mohty M , MarchettiN, El-CheikhJ, FaucherC, FurstS, BlaiseD. Rituximab as salvage therapy for refractory chronic GVHD.Bone Marrow Transplant.41(10), 909–911 (2008).
  • von Bonin M , OelschlagelU, RadkeJet al. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation 86(6), 875–879 (2008).
  • Canninga-van Dijk MR , van der StraatenHM, FijnheerR, SandersCJ, van den TweelJG, VerdonckLF. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease.Blood104(8), 2603–2606 (2004).
  • Okamoto M , OkanoA, AkamatsuSet al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 20(1), 172–173 (2006).
  • Cutler C , MiklosD, KimHTet al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108(2), 756–762 (2006).
  • Kim SJ , LeeJW, JungCWet al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, Phase II study. Haematologica 95(11), 1935–1942 (2010).
  • Teshima T , NagafujiK, HenzanHet al. Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. Int. J. Hematol. 90(2), 253–260 (2009).
  • Iguchi E , MinakataT, TsudoM. A case of membranous nephropathy associated with chronic GVHD successfully treated with rituximab.Bone Marrow Transplant.47(1), 132–134 (2012).
  • Mellon-Reppen S , RatanatharathornV, CroninS, UbertiJP. Repeated course of rituximab for treatment of nephrotic syndrome in patients with chronic GVHD.Bone Marrow Transplant.45(12), 1758–1759 (2010).
  • Kato I , UmedaK, AwayaTet al. Successful treatment of refractory donor lymphocyte infusion-induced immune-mediated pancytopenia with rituximab. Pediatr. Blood Cancer 54(2), 329–331 (2010).
  • George L , GeorgeB, GottliebDJ, HertzbergM, Fernandez-PenasP. Lack of efficacy of rituximab in refractory sclerodermatous chronic GVHD.Bone Marrow Transplant.47(5), 737–738 (2012).
  • Ruiz-Arguelles GJ , Gil-BeristainJ, MaganaM, Ruiz-DelgadoGJ. Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease.Biol. Blood Marrow Transplant.14(1), 7–9 (2008).
  • Zhou H , GuoM, BianCet al. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol. Blood Marrow Transplant. 16(3), 403–412 (2010).
  • Weng JY , DuX, GengSXet al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant. 45(12), 1732–1740 (2010).
  • Jedlickova Z , BurlakovaI, BugG, BaurmannH, SchwerdtfegerR, SchleuningM. Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors.Biol. Blood Marrow Transplant.17(5), 657–663 (2011).
  • Couriel DR , SalibaR, EscalonMPet al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br. J. Haematol. 130(3), 409–417 (2005).
  • Flowers ME , ApperleyJF, van BesienKet al. A multicenter prospective Phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 112(7), 2667–2674 (2008).
  • Perotti C , Del FanteC, TinelliCet al. Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. Transfusion 50(6), 1359–1369 (2010).
  • Jagasia MH , SavaniBN, StricklinGet al. Classic and overlap chronic graft-versus-host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP). Biol. Blood Marrow Transplant. 15(10), 1288–1295 (2009).
  • Lucid CE , SavaniBN, EngelhardtBGet al. Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT. Bone Marrow Transplant. 46(3), 426–429 (2011).
  • Doreau A , BelotA, BastidJet al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell Biology and the pathophysiology of systemic lupus erythematosus. Nat. Immunol. 10(7), 778–785 (2009).
  • Srinivasan M , FlynnR, PriceAet al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood 119(6), 1570–1580 (2012).
  • Gratwohl A , BrandR, FrassoniFet al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant. 36(9), 757–769 (2005).
  • Reusser P , RiddellSR, MeyersJD, GreenbergPD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease.Blood78(5), 1373–1380 (1991).
  • Sellar RS , PeggsKS. Management of multidrug-resistant viruses in the immunocompromised host.Br. J. Haematol.156(5), 559–572 (2012).
  • Winston DJ , YoungJA, PullarkatVet al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 111(11), 5403–5410 (2008).
  • Marty FM , LjungmanP, PapanicolaouGAet al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a Phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect. Dis. 11(4), 284–292 (2011).
  • Peggs KS , VerfuerthS, PizzeyA, ChowSL, ThomsonK, MackinnonS. Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation.Clin. Infect. Dis.49(12), 1851–1860 (2009).
  • Peggs KS . Adoptive T cell immunotherapy for cytomegalovirus.Expert Opin. Biol. Ther.9(6), 725–736 (2009).
  • Keenan RD , AinsworthJ, KhanNet al. Purification of cytomegalovirus-specific CD8 T-cells from peripheral blood using HLA-peptide tetramers. Br. J. Haematol. 115(2), 428–434 (2001).
  • Neudorfer J , SchmidtB, HusterKMet al. Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J. Immunol. Methods 320(1–2), 119–131 (2007).
  • Knabel M , FranzTJ, SchiemannMet al. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat. Med. 8(6), 631–637 (2002).
  • Assenmacher M , LohningM, RadbruchA. Detection and isolation of cytokine secreting cells using the cytometric cytokine secretion assay.Curr. Protoc. Immunol. Chapter 6, Unit 6.27 (2002).
  • Cobbold M , KhanN, PourgheysariBet al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med. 202(3), 379–386 (2005).
  • Yao J , BechterC, WiesnethMet al. Multimer staining of cytomegalovirus phosphoprotein 65-specific T-cells for diagnosis and therapeutic purposes: a comparative study. Clin. Infect. Dis. 46(10), e96–e105 (2008).
  • Schmitt A , TonnT, BuschDHet al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T-cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 51(3), 591–599 (2011).
  • Feuchtinger T , OpherkK, BethgeWAet al. Adoptive transfer of pp65-specific T-cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 116(20), 4360–4367 (2010).
  • Peggs KS , ThomsonK, SamuelEet al. Directly selected cytomegalovirus-reactive donor T-cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin. Infect. Dis. 52(1), 49–57 (2011).
  • Styczynski J , EinseleH, GilL, LjungmanP. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.Transpl. Infect. Dis.11(5), 383–392 (2009).
  • Heslop HE , SlobodKS, PuleMAet al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115(5), 925–935 (2010).
  • Uhlin M , OkasM, GertowJ, UzunelM, BrismarTB, MattssonJ. A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation.Cancer Immunol. Immunother.59(3), 473–477 (2010).
  • Moosmann A , BigalkeI, TischerJet al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T-cells. Blood 115(14), 2960–2970 (2010).
  • Sive JI , ThomsonKJ, MorrisEC, WardKN, PeggsKS. Adenoviremia has limited clinical impact in the majority of patients following alemtuzumab-based allogeneic stem cell transplantation in adults.Clin. Infect. Dis.55(10), 1362–1370 (2012).
  • Leen AM , MyersGD, SiliUet al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 12(10), 1160–1166 (2006).
  • Gerdemann U , VeraJF, RooneyCM, LeenAM. Generation of multivirus-specific T-cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant.J. Vis. Exp. (51), pii: 2736 (2011).
  • Zandvliet ML , van LiemptE, JedemaIet al. Simultaneous isolation of CD8+ and CD4+ T-cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation. J. Immunother. 34(3), 307–319 (2011).
  • Lugthart G , AlbonSJ, RicciardelliIet al. Simultaneous generation of multivirus-specific and regulatory T-cells for adoptive immunotherapy. J. Immunother. 35(1), 42–53 (2012).
  • Khanna N , StuehlerC, ConradBet al. Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154. Blood 118(4), 1121–1131 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.